FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1981248031> ?p ?o ?g. }

• W1981248031 endingPage "1762.e2" @default.
• W1981248031 startingPage "1755" @default.
• W1981248031 abstract "Background & AimsPentoxifylline, an inhibitor of tumor necrosis factor-α, is given to patients with liver diseases, but its effects in patients with advanced cirrhosis are unknown. We performed a randomized, placebo-controlled, double-blind trial of its effects in patients with cirrhosis.MethodsA total of 335 patients with cirrhosis (Child–Pugh class C) were assigned to groups given either pentoxifylline (400 mg, orally, 3 times daily; n = 164) or placebo (n = 171) for 6 months. The primary end point was mortality at 2 months. Secondary end points were mortality at 6 months and development of liver-related complications.ResultsBy 2 months, 28 patients in the pentoxifylline group (16.5%) and 31 in the placebo group (18.2%) had died (P = .84). At 6 months, 50 patients in the pentoxifylline group (30.0%) and 54 in the placebo group (31.5%) had died (P = .75). The proportions of patients without complications (eg, bacterial infection, renal insufficiency, hepatic encephalopathy, or gastrointestinal hemorrhage) were higher in the pentoxifylline group than in the placebo group at 2 months (78.6% vs 63.4%; P = .006) and 6 months (66.8% vs 49.7%; P = .002). The probability of survival without complications was higher in the pentoxifylline group than in the placebo group at 2 and 6 months (P = .04). In multivariate analysis, the factors associated with death were age, the Model for End-Stage Liver Disease score, and presence of early-stage carcinoma. Treatment with pentoxifylline was the only factor associated with liver-related complications.ConclusionsAlthough pentoxifylline does not decrease short-term mortality in patients with advanced cirrhosis, it does reduce the risk of complications. Pentoxifylline, an inhibitor of tumor necrosis factor-α, is given to patients with liver diseases, but its effects in patients with advanced cirrhosis are unknown. We performed a randomized, placebo-controlled, double-blind trial of its effects in patients with cirrhosis. A total of 335 patients with cirrhosis (Child–Pugh class C) were assigned to groups given either pentoxifylline (400 mg, orally, 3 times daily; n = 164) or placebo (n = 171) for 6 months. The primary end point was mortality at 2 months. Secondary end points were mortality at 6 months and development of liver-related complications. By 2 months, 28 patients in the pentoxifylline group (16.5%) and 31 in the placebo group (18.2%) had died (P = .84). At 6 months, 50 patients in the pentoxifylline group (30.0%) and 54 in the placebo group (31.5%) had died (P = .75). The proportions of patients without complications (eg, bacterial infection, renal insufficiency, hepatic encephalopathy, or gastrointestinal hemorrhage) were higher in the pentoxifylline group than in the placebo group at 2 months (78.6% vs 63.4%; P = .006) and 6 months (66.8% vs 49.7%; P = .002). The probability of survival without complications was higher in the pentoxifylline group than in the placebo group at 2 and 6 months (P = .04). In multivariate analysis, the factors associated with death were age, the Model for End-Stage Liver Disease score, and presence of early-stage carcinoma. Treatment with pentoxifylline was the only factor associated with liver-related complications. Although pentoxifylline does not decrease short-term mortality in patients with advanced cirrhosis, it does reduce the risk of complications." @default.
• W1981248031 created "2016-06-24" @default.
• W1981248031 creator A5001159444 @default.
• W1981248031 creator A5001302118 @default.
• W1981248031 creator A5003944446 @default.
• W1981248031 creator A5004361418 @default.
• W1981248031 creator A5014837668 @default.
• W1981248031 creator A5017307697 @default.
• W1981248031 creator A5033378708 @default.
• W1981248031 creator A5034322870 @default.
• W1981248031 creator A5071910351 @default.
• W1981248031 creator A5075393352 @default.
• W1981248031 creator A5079643491 @default.
• W1981248031 creator A5088338447 @default.
• W1981248031 date "2010-05-01" @default.
• W1981248031 modified "2023-10-18" @default.
• W1981248031 title "Pentoxifylline Does Not Decrease Short-term Mortality but Does Reduce Complications in Patients With Advanced Cirrhosis" @default.
• W1981248031 cites W1521442630 @default.
• W1981248031 cites W1962242957 @default.
• W1981248031 cites W1971033557 @default.
• W1981248031 cites W1992648385 @default.
• W1981248031 cites W2001288327 @default.
• W1981248031 cites W2002216094 @default.
• W1981248031 cites W2003357282 @default.
• W1981248031 cites W2007882007 @default.
• W1981248031 cites W2011375471 @default.
• W1981248031 cites W2018630692 @default.
• W1981248031 cites W2021565879 @default.
• W1981248031 cites W2033244806 @default.
• W1981248031 cites W2033634651 @default.
• W1981248031 cites W2044054951 @default.
• W1981248031 cites W2056879548 @default.
• W1981248031 cites W2065157394 @default.
• W1981248031 cites W2066064964 @default.
• W1981248031 cites W2069243984 @default.
• W1981248031 cites W2069940540 @default.
• W1981248031 cites W2070469742 @default.
• W1981248031 cites W2090588634 @default.
• W1981248031 cites W2101308992 @default.
• W1981248031 cites W2113743444 @default.
• W1981248031 cites W2116929627 @default.
• W1981248031 cites W2122230026 @default.
• W1981248031 cites W2133802811 @default.
• W1981248031 cites W2149449252 @default.
• W1981248031 cites W2152084270 @default.
• W1981248031 cites W2153166528 @default.
• W1981248031 cites W2165252059 @default.
• W1981248031 cites W2305357429 @default.
• W1981248031 cites W2314673390 @default.
• W1981248031 cites W2322121630 @default.
• W1981248031 cites W4251782759 @default.
• W1981248031 doi "https://doi.org/10.1053/j.gastro.2010.01.040" @default.
• W1981248031 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20102716" @default.
• W1981248031 hasPublicationYear "2010" @default.
• W1981248031 type Work @default.
• W1981248031 sameAs 1981248031 @default.
• W1981248031 citedByCount "126" @default.
• W1981248031 countsByYear W19812480312012 @default.
• W1981248031 countsByYear W19812480312013 @default.
• W1981248031 countsByYear W19812480312014 @default.
• W1981248031 countsByYear W19812480312015 @default.
• W1981248031 countsByYear W19812480312016 @default.
• W1981248031 countsByYear W19812480312017 @default.
• W1981248031 countsByYear W19812480312018 @default.
• W1981248031 countsByYear W19812480312019 @default.
• W1981248031 countsByYear W19812480312021 @default.
• W1981248031 countsByYear W19812480312022 @default.
• W1981248031 countsByYear W19812480312023 @default.
• W1981248031 crossrefType "journal-article" @default.
• W1981248031 hasAuthorship W1981248031A5001159444 @default.
• W1981248031 hasAuthorship W1981248031A5001302118 @default.
• W1981248031 hasAuthorship W1981248031A5003944446 @default.
• W1981248031 hasAuthorship W1981248031A5004361418 @default.
• W1981248031 hasAuthorship W1981248031A5014837668 @default.
• W1981248031 hasAuthorship W1981248031A5017307697 @default.
• W1981248031 hasAuthorship W1981248031A5033378708 @default.
• W1981248031 hasAuthorship W1981248031A5034322870 @default.
• W1981248031 hasAuthorship W1981248031A5071910351 @default.
• W1981248031 hasAuthorship W1981248031A5075393352 @default.
• W1981248031 hasAuthorship W1981248031A5079643491 @default.
• W1981248031 hasAuthorship W1981248031A5088338447 @default.
• W1981248031 hasBestOaLocation W19812480311 @default.
• W1981248031 hasConcept C126322002 @default.
• W1981248031 hasConcept C141071460 @default.
• W1981248031 hasConcept C142724271 @default.
• W1981248031 hasConcept C204787440 @default.
• W1981248031 hasConcept C27081682 @default.
• W1981248031 hasConcept C2777214474 @default.
• W1981248031 hasConcept C2778384902 @default.
• W1981248031 hasConcept C2780325230 @default.
• W1981248031 hasConcept C2780404050 @default.
• W1981248031 hasConcept C71924100 @default.
• W1981248031 hasConcept C90924648 @default.
• W1981248031 hasConceptScore W1981248031C126322002 @default.
• W1981248031 hasConceptScore W1981248031C141071460 @default.
• W1981248031 hasConceptScore W1981248031C142724271 @default.
• W1981248031 hasConceptScore W1981248031C204787440 @default.
• W1981248031 hasConceptScore W1981248031C27081682 @default.

• next